Medical News

RSS

Scientists identify key tumorigenic pathways in never-smoker lung adenocarcinoma patients

Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers - a first step in developing potential therapeutic targets.

9 Jan 2012

BerGenBio completes $8.8M Series A financing round

BerGenBio AS, an emerging oncology biopharma company, today announced it has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic.

9 Jan 2012

Middle-aged adults with diabetes have time to learn how to control hypertension

A new study suggests that middle-aged adults recently diagnosed with diabetes and hypertension have time to try to learn how to control their high blood pressure without medications, but not too much time.

9 Jan 2012

Enrollment complete in Diamyd Phase II study for type 1 diabetes

A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd. The study is thus fully recruited.

9 Jan 2012

Shire, ICON sign strategic partnership agreement

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that is has signed a strategic partnership with Shire Specialty Pharmaceuticals to serve as the sole global provider of central laboratory services and one of two strategic partners for clinical development services.

9 Jan 2012

Many parents share BRCA1/A2 test results with their children

A new study has found that when parents get tested for breast cancer genes, many of them share their results with their children, even with those who are very young. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that most parents think that their children are not distressed when they learn about the test results.

9 Jan 2012

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus protection.

9 Jan 2012

miRagen, Silence partner to assess delivery potential of novel miRNA-based therapeutics

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, announces that it has signed an agreement with miRagen Therapeutics, Inc., to assess the delivery potential of Silence's proprietary DBTC delivery system with miRagen's novel microRNA-based therapeutics.

9 Jan 2012

NYU medical students use online 3D interactive virtual human body

First-year students at NYU School of Medicine were introduced to a pioneering online 3D interactive virtual human body called the BioDigital Human. This unique educational experience supplements the traditional use of human cadavers in anatomy instruction by allowing students to both view and interact with realistically simulated 3D organs and other anatomical structures.

9 Jan 2012

MPIIB, QIAGEN partner to develop latent TB diagnostic test

QIAGEN N.V. and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.

From QIAGEN Manchester Limited 9 Jan 2012

Romney testy about contraception hypothetical at GOP debate

News outlets covered tonight's debate at St. Anselm College, three days before the New Hampshire primary. In the first of 2 debates over 12 hours, the health law, Medicare or Medicaid were not discussed.

9 Jan 2012

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

9 Jan 2012

Scientists identify two genes involved in major symptoms of MeCP2 duplication disorder

The anxiety and behavioral issues associated with excess MeCP2 protein result from overexpression of two genes (Crh [corticotropin-releasing hormone] and Oprm 1 [mu-opioid receptor MOR 1]), which may point the way to treating these problems in patients with too much of the protein, said Baylor of Medicine scientists in a report that appears online in the journal Nature Genetics.

8 Jan 2012

AICAR therapy may combat heat stroke

We've all seen the story in the news before. Whether it's the death of a physically fit high school athlete at football training camp in August, or of an elderly woman gardening in the middle of the day in July, heat stroke is a serious, life-threatening condition for which there is no treatment beyond submersion in ice water or the application of ice packs to cool the body to a normal temperature.

8 Jan 2012

Scientists develop simple, reliable test to identify biomarkers for MPS

A team of scientists, led by researchers at the University of California, San Diego School of Medicine and Zacharon Pharmaceuticals, have developed a simple, reliable test for identifying biomarkers for mucopolysaccharidoses (MPS), a group of inherited metabolic disorders that are currently diagnosed in patients only after symptoms have become serious and the damage possibly irreversible.

8 Jan 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

NCH voluntarily recalls certain over-the-counter drugs in the U.S.

Novartis Consumer Health, Inc. (NCH) announced today that it is voluntarily recalling all lots of select bottle packaging configurations of Excedrin and NoDoz products with expiry dates of December 20, 2014 or earlier as well as Bufferin and Gas-X Prevention products with expiry dates of December 20, 2013 or earlier, in the United States.

8 Jan 2012

HCA issues commitment to offer full support to PIP breast implant patients

Last Friday the MHRA advised that they found no evidence to support routine removal of PIP breast implants and they recommended that any patients who were concerned about their implant should seek clinical advice from their consultant surgeon.

8 Jan 2012

Bristol-Myers Squibb signs definitive agreement to acquire Inhibitex

Bristol-Myers Squibb Company and Inhibitex, Inc. announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger.

8 Jan 2012

Proteomics: Thermo Fisher Scientific and PREMIER Biosoft to co-market SimGlycan software

Thermo Fisher Scientific Inc., the world leader in serving science, and PREMIER Biosoft, have announced an agreement to co-market PREMIER Biosoft’s SimGlycan® software. The agreement aims to advance glycobiology by dramatically speeding the characterization of complex glycans through automated interpretation of the rich data produced by Thermo Scientific mass spectrometer systems.

From Thermo Fisher Scientific Inc. 8 Jan 2012